Drugs and FDA
FDA rejects Summit and Akeso’s ivonescimab application for lung cancer
The FDA rejected ivonescimab plus chemotherapy for EGFR-mutated advanced NSCLC because the HARMONi trial did not show a statistically significant overall survival benefit.

Summit Therapeutics said the FDA issued a complete response letter rejecting its application for ivonescimab with platinum-containing chemotherapy to treat EGFR-mutated, locally advanced or metastatic non-small cell lung cancer. The application covered patients whose disease had progressed after EGFR tyrosine kinase inhibitor treatment. Ivonescimab was developed by Akeso, which licensed U.S. rights to Summit.
In the phase III HARMONi trial, median progression-free survival was 6.8 months with ivonescimab and 4.4 months with placebo, according to the reports. Median overall survival was 16.8 months and 14 months, respectively, but the difference was not statistically significant. Summit said the FDA did not consider the progression-free survival result, without a statistically significant overall survival benefit, enough to support approval. BioPharma Dive reported that Summit and Akeso expected results by the end of the year from a separate trial comparing ivonescimab and chemotherapy with Keytruda and chemotherapy as a first-line lung cancer treatment.


